News and Comments

Vertex and Merck KGaA Agreement Suits Both Firms

  Friday, January 13, 2017

Vertex (VRTX) entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development and commercialization of four research and development programs that the firm believes represent novel approaches to cancer treatment  More...

Moderna Is a Private Revolutionary Biotech Firm That Investors Should Not Ignore

  Tuesday, July 26, 2016

We love to present to you Moderna, a firm that, we believe, is building revolutionary pipeline products. We mean it when we say revolutionary. The time has come for Moderna to be heard of by serious investors. It is still private, but it is revolutionary and is working with the publicly-traded firms AstraZeneca (AZN), Merck (MRK), and Vertex (VRTX) to bring what we believe will be game changing approaches for the management of intractable, untreatable and deadly diseases.   More...

VERTEX: Orkambi Approved In Europe. What Vertex is Doing to Further improve CF Treatments

  Friday, November 20, 2015

Europe Approves Orkambi®  More...


  Wednesday, September 05, 2012



  Tuesday, May 15, 2012

The time has come for redefining the meaning of “creating shareholders value” in the biotech sector. Pinpointing the real value has become imperative. It is the road to a fair assessment of innovative biotech firms. It helps investors reap the fruits of the real value of excellent firms at the right time, rather than rush to sell extremely promising stocks while still undervalued. It makes investors think twice before throwing their shares of firms that are installing one by one the building blocks of their vision. Creating shareholders value is investing in the future. The cost of this investment shouldn’t be cause for downgrading the stocks because of overspending, which has become a normal pattern. We still see all development-stage biotech stock prices slashed following the announcement of their quarterly results. There is a big difference between spending on the future and spending because the money has been made available. Investors can know the difference. The first thing to look for is whether the firm has any program in development that is worth spending on, including buying firms having a technology that is badly required for the successful outcome of the firm’s program. This kind of investment should not be punished or treated as unnecessary spending. More...

FDA Approves KALYDECO™ (ivacaftor) The First Medicine to Treat the Underlying Cause of Cystic Fibrosis

  Tuesday, January 31, 2012

The U.S. Food and Drug Administration (FDA) has approved KALYDECOTM (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), a rare, genetic disease. KALYDECO  is approved for people with CF ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. More...

VERTEX: First Drugs ever to target the root-cause of cystic fibrosis are promising.

  Monday, June 13, 2011

Like many other chronic progressive intractable diseases, Cystic Fibrosis (CF) pathology is about misfolding of the transmembrane conductance regulator (CFTR) protein as a result of CFTR gene mutations. The malfunctioning CFTR protein loses its trafficking capability and fails to reach the cell membrane, resulting in the accumulation of thick, sticky mucus that plugs the airways and chokes the pancreas. The symptoms are chronic coughing, difficulty breathing, malabsorption of food and nutrients from the intestine, inability to gain weight, diarrhea, or bulky, foul-smelling, greasy stools, or constipation. The disease is debilitating and affects about 100,000 babies, children and adults worldwide. The presence of salty skin confirms the diagnosis of the disease. More...

VERTEX: What About Now?

  Wednesday, May 25, 2011

Yesterday, the FDA approved Incivek (telaprevir), Vertex’ (VRTX) HCV protease inhibitor, which demonstrated in clinical trials it cures more treatment naïve patients and more patients who did not benefit from conventional treatments in much less time than Merck’s Victrelis (boceprevir). Less than a month ago, the FDA Antiviral Drugs Advisory Committee voted 18-0 to recommend approval Incivek for HCV patients with genotype 1 chronic hepatitis. The recommendation was based on clinical trial data demonstrating that combining Incivek with pegylated interferon/ribavirin produced a higher cure rate in less time than standard therapy alone. This improvement is most notable for hard-to-treat patients including those with HCV genotype 1, people with liver cirrhosis, and those who did not respond to a prior course of conventional. Merck's drug Victrelis (boceprevir) also an HCV protease inhibitor, was given a positive recommendation and was eventually approved. More...


  Thursday, May 05, 2011

First, we congratulate our subscribers who did not follow the skeptics and believed in the rationality of science and kept their Vertex’ (VRTX) and Regeneron’s (REGN) shares despite years of negative campaigns against the two firms. Following the rally in VRTX, another rally started in REGN for rational reasons. Both firms are among our TOP TEN selection. More...

VERTEX: Time For Celebration

  Wednesday, April 13, 2011

From no treatment at all, to treatments that do not work well, new therapies are reaching the market, probably this month or next, moving hepatitis C virus (HCV) victims from the dark zone of desperation into the light of amazing anticipation – probably of a cure. We don’t know if the opening statement is one of those run-on sentences, from which you might have lost your breath trying to read it to your spouse, but we know with certainty that the news coming from Vertex’ (VRTX) drug is breathtaking. The road has been long, very long, yet, this is always the case when new molecules are designed to become drugs for life-threatening diseases that have yet to find treatments. The fact is that it is a real miracle just finding a road towards conquering a disabling virus that disrupts the functioning of one of the major vital organs. HCV could cause fibrosis (cirrhosis) of the liver, which could, sometimes, necessitate liver transplant or cause cancer. More...

Recent Postings



NEUROCRINE (NBIX) Trastuzumab-DM1 Adaptimmune (ADAP) SYNTA (SNTA) Ionis (IONS) Human Genome Sciences (HGSI) Multiple Myeloma Spike Therapeutics (ONCE) NEKTAR (NKTR)) Epizyme (EPZM) Exelixis (EXEL) ARGOS (ARGS) HALOZYME (HALO) Prolor Biotech (PBTH) KITE (KITE) OSI (OSIP) Alnylam (ALNY) Dendreon (DNDN) Global Cell Therapeutics (GBT) GUARDIAN HEALTH Vitae Pharmaceuticals (VTAE) GlycoMimetics (GLYN) Valeant Pharmaceuticals International (VRX) OncoCyte (OCX) IDERA (IDRA) Abbott Laboratories (ABT) Bellicum (BLCM) Velcade (bortezomib) JOUNCE THERAPEUTICS (JNCE) GlaxoSmithKline (GSK) Gilead (GILD) Alder Biopharmaceuticals (ALDR) Aimmune Therapeutics (AIMT) AGOS (ARGS) Mirati Therapeutics (MRTX) AERIE PHARMACEUTICALS Illumina (ILMN) Ariad (ARIA) ISIS (ISIS) ZALTRAP™ Intrexon (XON) Sangamo (SGMO) Prosensa (RNA) Seattle Genetics (SGEN) Array Pharmaceuticals (ARRY) Merck (MRK) CRISPR Therapeutics (CRSP) ARCA (ABIO) MODERNA Tysabri ABBVIE (ABBV) Intermune (ITMN) INNOVIVA (INVA) NOVOCURE (NVCR) CompuGen (CGEN) Pluristem (PSTI) KERYX (KERX) NANTKWEST (NK) Agenus (AGEN) CEMPRA (CEMP) Biogen Idec (BIIB) Revlimid (lenolidamide) Onyx (ONXX) Anadys (ANDS) LEXICON (LXRX) Micromet (MITI) Inovio (INO) ADVENTRIX (ANX) Amgen (AMGN) AstraZeneca (AZN) ImmunoGen (IMGN) Roche (ROCHE) Xoma (XOMA) Theravance Bio Pharma (TBPH) Sanofi-Aventis (SAN) Roche (RHHBY) Agenus (AGEN Telaprevir Intercept (ICPT) Vertex (VRTX) Benlysta (belimumab) Theravance (THRX) Sanofi (SNY) PORTOLA (PTLA) Human Longevity (HLI) Regeneron (REGN) Genentech REGULUS (RGLS) Editas (EDIT) Ridaforolimus Sanofi (SNA) Akebia Therapeutics (AKAB) Cytokinetics (CYTK) TOKAI (TKAOI) Sarepta (SRPT) ACADIA (ACAD) Idenix (IDIX) RenenxBio (RGNX) Endometrial Cancer Jazz Pharmaceuticals (JAZZ) Bristol-Myers Squibb (BMY) Biocryst (BCRX) SERES THERAPEUTICS (MCRB) BIOMARIN (BMRN) C4 Therapeutics Rapamune VANDA (VNDA) galapagos (GLPG) Zerenex Anacor (ANAC) SUNESIS PHARMACEUTICALS (SNSS) Auspex (ASPX) Ziofpharm (ZIOP) Herceptin Sequenom (SQNM) Galena (GALE) Advaxis (ADXS) Dynavax (DVAX) Elan (ELN) JUNO (JUNO) PTC Therapeutics (PTCT) Ocular Therapeutix (OCUL) Incyte (INCY)